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A sensitive and selective method based on gas chromatography hyphenated to mass spectrometry (GC–
MS) was developed and validated for the determination of atractylon in rat plasma. Plasma samples were
processed by liquid–liquid extraction with ethyl acetate-n-hexane (1:1, v/v) using acetophenone as an
internal standard (IS). Analytes were determined in selective ion monitoring (SIM) mode using target
ions at m/z 108.1 for atractylon and m/z 105.1 for acetophenone. The calibration curve was linear over the
concentration range of 10–1000 ng/mL with lower limit of quantiﬁcation of 10 ng/mL. The intra- and
inter-day precision variations were not more than 10.4% and 9.6%, respectively, whilst accuracy values
ranged from 6.5% to 4.9%. Extraction recovery of the assay was satisfactory. This method was suc-
cessfully applied to quantiﬁcation and pharmacokinetic study of atractylon in rat plasma after in-
tragastric administration of Atractylodis extract.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atractylodis (the dried root and stem of Atractylodes macro-
cephala Koidz), commonly known as the ‘Baizhu’, is a traditional
Chinese medicine (TCM) used for the treatment of lenic asthenia,
anorexia, excessive perspiration and abnormal fetal movement [1].
Atractylodis exerts a variety of pharmacological effects such as
anti-tumor, anti-inﬂammatory, anti-bacterial and anti-aging ef-
fects [2–5]. Some studies demonstrated that intragastric admin-
istration of a decoction made from Atractylodis has signiﬁcantly
increased the immune response induced by a foot-and-mouth
disease vaccine in mice [6]. In regard to its chemical constituents,
the major ingredients of Atractylodis are atractylon (Fig. 1),
atractylenolides I, II, and III [7]. Atractylon is the main active in-
gredient of Atractylodis [8,9]. This compound exhibits various
pharmacological activities including anti-inﬂammation, anti-tu-
mor, cytotoxicity against various human cancer cell lines and in-
hibition of Naþ ,Kþ-ATPase activity [10–14].
There are many analytical methods including gas chromato-
graphy–mass spectrometry (GC–MS) [15], microbore liquid chro-
matography (microbore LC) [16] and high performance liquid
chromatography (HPLC) [17,18] reported for determining atractylonon and hosting by Elsevier B.V. All
University.
5.
li76@163.com (Y. Zhao).contained in the crude herb. However, none of these methods have
been used for pharmacokinetic studies of atractylon in biological
samples. Pharmacokinetic studies of the active ingredients in herbal
medicine will contribute substantially to elucidation of their me-
chanisms of action and development of the quality of herbal med-
icine. We developed a sensitive and selective GC–MS method for
the determination of atractylon in rat plasma using acetophenone
(Fig. 1) as an internal standard (IS) after liquid–liquid extraction
(LLE) with ethyl acetate–n-hexane (1:1, v/v). The method was fully
validated and applied to the pharmacokinetic study after in-
tragastric administration of Atractylodis extract to rats. It was ex-
pected that the results of this study would provide some references
for the comprehension of the action mechanism and further phar-
macological study of atractylon.2. Materials and methods
2.1. Materials, reagents and animals
The crude herb, Atractylodes macrocephala Koidz, was pur-
chased from Beijing TongRenTang (Shenyang, China). The raw
herbal materials were authenticated by Professor Zhiguo Yu
(School of Pharmacy, Shenyang Pharmaceutical University, She-
nyang, China). Atractylon (purity Z98%) was purchased from
Jianglai Biological Technology Company Limited (Shanghai, China).rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. The product ion mass spectra of atractylon and acetophenone.
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acetonitrile and ethyl acetate (HPLC grade) were purchased from
the Concord Tech Reagent Company (Tianjin, China).
Male Sprague-Dawley (SD) rats, weighing 200720 g, were
obtained from Experimental Animal Center of Shenyang Phar-
maceutical University (China) and bred with unlimited access to
food and water in an air-conditioned animal center at the
temperature of 2272 °C and relative humidity of 50%710%
with a natural light–dark cycle. They were fasted with only ac-
cess to water for 12 h prior to the experiment. Animal experi-
ment was carried out according to the Guideline for Animal
Experimentation of Shenyang Pharmaceutical University, and
the protocol was approved by the Animal Ethics Committee of
the institution.
2.2. Apparatus and operation conditions
2.2.1. Instrumentation and GC–MS conditions
6890N gas chromatography system was ﬁtted with a 5975 mass
selective detector of Agilent Technologies (Palo, Alto, CA, USA). GC
separation was accomplished on HP-5MS column (30 m0.25 mm,
0.25 mm), employed with helium as a carrier gas at a ﬂow rate of
1.0 mL/min. An aliquot (5 mL) of the plasma sample extract was in-
jected in splitless mode. The solvent delay before the MS ﬁlament
turned on was set to 2 min to protect the ﬁlament from oxidation.
Electron impact (EI) ionization modewas used with nominal electron
energy (70 eV). The temperatures of EI ion source, quadrupole mass
analyzer, and the interface were maintained at 230, 150 and 250 °C,
respectively. The column temperature was programmed as follows.
Initially, the column temperature was maintained at 90 °C for 2 min,
then increased at a rate of 25 °C/min to 150 °C, followed by an in-
crease at a rate of 10 °C/min to 200 °C, and increased at a rate of
25 °C/min to 260 °C for at least 3 min. The full scan range of the
sample for the qualitative analysis was fromm/z 30 tom/z 500. Fig. 1
shows the mass spectra of atractylon and acetophenone. GC–MS
was performed in the selective ion monitoring (SIM) mode using
target ions at m/z 108.1 for atractylon and m/z 105.1 for acet-
ophenone (IS).
2.2.2. Preparation of Atractylodis extract
Powdered Atractylodis (200 g) was extracted with 1000 mL of
ethanol–water (95:5, v/v) by reﬂuxing (1.0 h). Then the extraction
solutions were evaporated to dryness using rotary evaporator at a
maximum temperature of 50 °C and made to a concentration of
5 g of raw herbal materials per milliliter. The content of atractylonin Atractylodis extract was quantiﬁed by external standard method
using the same chromatography conditions as described above.
The content of atractylon in Atractylodis extract was 56.5 mg/mL.
2.2.3. Preparation of stock solutions, calibration standards and
quality control samples
Stock solutions of atractylon and IS were prepared in ethanol at
a concentration of 1000 and 40 mg/mL. The stock solution of
atractylon was diluted with ethanol at a concentration range of
0.2–20 mg/mL, which were used as the working solutions in the
linearity experiment. The internal standard solution was obtained
by diluting the IS stock solution to a concentration of 4 mg/mL. All
solutions were stored at 4 °C prior to use.
Calibration standard samples were prepared by spiking 100 mL
of blank rat plasma with 5 mL of working solutions. Quality control
(QC) samples were also prepared in the same way, using a sepa-
rately weighed stock solution. The standard and QC samples were
extracted on each analysis day with the same procedures for
plasma samples as described below.
2.3. Plasma sample preparation
A simple LLE method was applied to extract atractylon and IS
from rat plasma. To 100 mL of the rat plasma, 5 mL of the IS and 5 mL
of ethanol (volume of the corresponding working solution for
calibration curve and QC samples) were added. Then the mixture
was vortexed for 30 s and extracted with 100 mL of ethyl acetate-n-
hexane (1:1, v/v) by shaking on a vortex mixer for 5 min at room
temperature. After centrifugation at 13,000 rpm (4 °C) for 5 min,
5 mL of the supernatant was injected into the GC–MS for analysis.
2.4. Method validation
The method was validated in terms of speciﬁcity, linearity,
precision and accuracy, extraction recovery and stability.
2.4.1. Speciﬁcity
The speciﬁcity of the method was demonstrated by comparing
chromatograms obtained from blank plasma samples (from six
different drug-free rats), plasma samples spiked with atractylon
and the IS, and plasma samples obtained from rats after in-
tragastric administration of Atractylodis extract.
2.4.2. Linearity and the lower limit of quantiﬁcation (LLOQ)
Calibration standard samples were prepared by spiking 100 mL
of blank rat plasma with 5 mL of working solutions. The plasma
concentration range was 10–1000 ng/mL for atractylon. Calibra-
tion curves were created by plotting the peak area ratio of the
analyte to internal standard versus concentrations of the analyte in
plasma with 1/x2 weighted regression. The LLOQ was deﬁned as
the lowest concentration point of the calibration curve determined
with an acceptable deviation from the nominal concentration
(720%). Moreover, signal-to-noise ratio (S/N) of the analyte at this
concentration level was at least 10.
2.4.3. Precision and accuracy
QC samples containing atractylon at low, medium and high
concentrations of 20, 100, and 800 ng/mL were independently
prepared for evaluation of precision and accuracy. The intra- and
inter-day precisions and accuracies were determined by assaying
six replicates of QC samples at three different concentrations on
three consecutive days. The variability of determination was de-
picted as the relative error (RE%) and relative standard deviation
(RSD%), respectively. The RE% and RSD% should not exceed 15%.
H. Yan et al. / Journal of Pharmaceutical Analysis 5 (2015) 327–331 3292.4.4. Extraction recovery
Extraction recovery was determined by comparing the peak
areas obtained from analytes in plasma samples which had been
spiked with analytes before extraction with those obtained from
samples to which analytes had been added after extraction. Ex-
traction recovery was tested at three QC levels in six replicates and
should be stable.
2.4.5. Stability
The stability of atractylon was examined by analyzing replicates
(n¼3) of three levels of QC samples under different conditions.
Freeze–thaw stability was evaluated after three cycles of 20 to
20 °C. Long-term stability was evaluated by placing plasma sam-
ples at 20 °C for 7 days. The short-term stability was assessed by
analyzing samples kept at room temperature for 5 h. The samples
were considered stable if the assay values were within an accep-
table deviation from the nominal concentration (715%).
2.5. Pharmacokinetic study
This validated method was applied to monitor the plasma
concentrations of atractylon in rats after intragastric administra-
tion of 10 mL/kg of Atractylodis extract (equivalent to 565 mg/kg
atractylon). Serial blood samples (approximately 0.3 mL) were
collected from fosse orbital vein into 1.5 mL heparinized tubes at 0,Fig. 2. Representative chromatograms of (A) acetophenone and (B) atractylon in (1) bla
samples obtained from rats at 6 h after intragastric administration of Atractylodis extra0.17, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 h after intragastric administration
of Atractylodis extract. Blood samples were immediately cen-
trifuged at 4000 rpm for 10 min. 100 mL of supernatant plasma was
transferred into another tube and stored at 20 °C until analysis.
Pharmacokinetic parameters of atractylon were calculated by non-
compartmental analysis of plasma concentration versus time data
using DAS 2.1 pharmacokinetic program (Chinese Pharmacological
Society).3. Results and discussion
3.1. Method development and optimization
A GC–MS method was developed and optimized for determi-
nation of atractylon in rat plasma. An HP-5 capillary column was
used for the chromatographic separation. Chromatographic con-
ditions were optimized through several trials to obtain high re-
solution and relative symmetric peak shapes. Chromatographic
conditions like initial (40, 90, 120, and 150 °C) and ﬁnal (220, 240,
and 260 °C) column temperatures, the column temperature rate
(5, 10, 20, and 25 °C/min) and the carrier gas ﬂow rate (0.5, 0.8,
and 1.0 mL/min) were optimized. The optimized GC separation of
analytes was achieved within 15 min, and the retention time of
acetophenone and atractylon was 3.8 and 8.9 min, respectively.nk plasma, (2) blank plasma spiked with atractylon at LLOQ and IS, and (3) plasma
ct.
Table 2
Stability of atractylon under various storage conditions (n¼3).
Nominal conc.
(ng/mL)
Three freeze–
thraw cycles
Storage at 20 °C
for 7 days
Room temperature
for 5 h
RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%)
20 9.7 5.3 11.2 4.1 8.2 7.4
100 6.9 2.0 7.2 3.7 4.9 5.8
800 5.9 3.1 6.9 4.1 5.3 4.9
Fig. 3. Mean plasma concentration–time curves of atractylon after intragastric
administration of Atractylodis extract (mean7SD, n¼6).
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the study was selected to avoid the analytical interference of en-
dogenous substance and achieve required selectivity. According to
the relative abundance of each fragment ion in mass spectra
(Fig. 1), analytes were determined using target ions at m/z 108.1
for atractylon and m/z 105.1 for acetophenone (IS).
Sample preparation plays an important role in determination of
analytes in biological samples. Protein precipitation method was
initially attempted with methanol or acetonitrile. However, this
technique resulted in low recovery. To obtain clean sample and
satisfactory recovery, the LLE method was explored with several
organic solvents including diethyl ether, n-hexane, ethyl acetate,
ethyl acetate–n-hexane (1:1, v/v) and ethyl acetate–n-hexane (2:8,
v/v). After several trials, LLE with ethyl acetate–n-hexane (1:1, v/v)
was found to be suitable for determination of atractylon in rat
plasma.
3.2. Method validation
3.2.1. Speciﬁcity
Fig. 2 represents typical chromatograms of blank plasma, blank
plasma spiked with atractylon and the IS, and rat plasma sample
collected at 6 h after intragastric administration of Atractylodis
extract. Blank rat plasma yielded relative clean chromatograms
without interfering peaks both to the analyte and IS.
3.2.2. Linearity and LLOQ
The calibration curves showed good linearity over the con-
centration range of 10–1000 ng/mL in rat plasma. A typical equa-
tion of the calibration curves was y¼3.81103xþ2.78102
(r¼0.9905), where y is the peak area ratio of atractylon to IS, and x
is the concentration of atractylon. The LLOQ for atractylon in rat
plasma was 10 ng/mL, which was sufﬁcient for the pharmacoki-
netic study.
3.2.3. Precision and accuracy
The intra- and inter-day precisions and accuracies of atractylon
are summarized in Table 1. The RSD% values were not more than
10.4% and the RE values were all within 6.5% to 4.9%. Results of
intra- and inter-day analyses indicated that the proposed GC–MS
method was accurate, reliable and reproducible for the quantita-
tive analysis of atractylon in rat plasma samples.
3.2.4. Extraction recovery
Extraction recovery data of atractylon are shown in Table 1.
Mean absolute recoveries of atractylon from rat plasma were
91.6%–95.9% at three QC levels, and the extraction efﬁciency of IS
was 93.6%73.4%, which could meet the requirements of analysis.
These data indicated that the single-step LLE with ethyl acetate–n-
hexane (1:1, v/v) used in the experiment proved to be successful.
3.2.5. Stability
The results of the stability study showed that there was no
obvious substance loss under the conditions that plasma samplesTable 1
Precision, accuracy and recovery of atractylon in rat plasma (n¼6).
Nominal
conc.
(ng/mL)
Intra-day Inter-day Recovery
Precisin
(RSD%)
Accuracy
(RE%)
Precisin
(RSD%)
Accuracy
(RE%)
(Mean7SD, %)
20 10.4 5.2 9.6 4.9 92.974.6
100 8.3 3.9 5.2 6.5 95.973.1
800 5.9 4.2 6.3 3.7 91.674.8might experience during this study. The results are summarized in
Table 2.
3.3. Pharmacokinetic study
The validated GC–MS method was successfully applied to the
pharmacokinetic study of atractylon in rat plasma following in-
tragastric administration of Atractylodis extract. The mean plasma
concentration–time proﬁle of atractylon is shown in Fig. 3. The
pharmacokinetic parameters including half-time (t1/2), average
dwell time (MRT(0–t) and MRT(0–1)), maximum plasma con-
centration (Cmax), time to reach the maximum concentrations
(tmax), and area under the plasma concentration–time curve
(AUC0-t and AUC0-1) estimated with DAS software using non-
compartment model are shown in Table 3. These data showed that
low levels of atractylon were seen after a relatively high oral dose.4. Conclusion
A simple, rapid and sensitive GC–MS method was developed
and validated for the quantiﬁcation of atractylon in rat plasma.
With no report on GC–MS method for the determination and
pharmacokinetic study of atractylon, this is the ﬁrst report onTable 3
Main pharmacokinetic parameters of atractylon after intragastric administration of
Atractylodis extract (n¼6).
Parameters Mean7SD
AUC0–t (ng h/mL) 1386.67525.0
AUC0–1 (ng h/mL) 1533.77477.0
MRT0–t (h) 6.4270.69
MRT0–1 (h) 9.7973.83
t1/2 (h) 7.6473.42
tmax (h) 1.8370.41
Cmax (ng/mL) 257.17125.1
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tragastric administration of Atractylodis extract. The method pre-
sented is valuable for future clinical studies.Acknowledgments
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